Mechanism of Action and Pathways to Vascular Stability

Dr. John Kitchen, from the Retina Associates of Kentucky, talks about the mechanisms of action and therapeutic advantages of aflibercept, a bispecific fusion protein targeting VEGF-A, VEGF-B and placental growth factor. Unlike other anti-VEGF therapies, aflibercept exhibits superior binding affinity and a longer half-life, effectively inhibiting downstream signalling through VEGF receptors 1 and 2. This comprehensive inhibition reduces vascular permeability, inflammation and neovascularisation, addressing key pathophysiological factors in diseases like diabetic macular oedema and neovascular age-related macular degeneration.